Experiential HIV Testing Increasing Testing Related Knowledge and Practice, and Reduce Stigma Toward HIV of Nurses.

September 11, 2025 updated by: Piao-Yi Chiou, National Taiwan University

The Effects of Experiential HIV Testing to Improve Knowledge and Practice, and Reduce Stigma Toward HIV of Emergency Department Nurses

This is a randomized controlled trial design. The investigators plan to recruit about 60 to 70 emergency department nurses from a medical center in Taipei, Taiwan. After completing the paper consent form, these nurses will be randomly assigned to 2 groups, which are a control group and an experimental group. The pre-test includes the demographic data sheet, HIV testing related knowledge and practice scale, and The Health Care Provider HIV/ AIDS Stigma Scale (HPASS). All nurses will receive a learning material when they finish the pre-test. In addition, the experimental group will be provided a real HIV testing and counselling by a researcher. The post-test will be finished one month later of pre-test in the control group, and one month later while the intervention completed in the experimental group. The semi-structural interview will be performed to the experimental group to collect and analyze their opinion toward the experiential HIV testing.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This project aims to develop an intervention of "experiential HIV testing" and to verify the following effects on emergency nurses: (1) Improve HIV testing related knowledge and practice; (2) Reduce HIV-related stigma; (3) Find out the possible demographic factors that might affect the effectiveness of experiential HIV Testing. During the intervention, nurses can directly participate in the whole process of anonymous HIV testing in the role of who need to be screened, and pre- and post-testing counselling accompanied the education and discussion will also be provided to them by a researcher. Through the above-mentioned measures, the knowledge and practices related to the HIV testing could be improved, and the stigma attitude toward HIV could be reduced through the self-reflection on the testing process.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
74

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: PIAO-YI CHIOU, Doctoral
  • Phone Number: 288427 +886-2-2312-3456
  • Email: piaoyi@ntu.edu.tw

Study Locations

  • Taiwan
      • Taipei, Taiwan, 100
        • School of Nursing of National Taiwan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- have registered nurse license and do clinical care in emergency department

Exclusion Criteria:

  • have registered nurse license but doesn't do clinical care, likes head nurse.
  • do clinical care in emergency department but doesn't have registered nurse license, like volunteers or assistant nurse.
  • have experienced non-occupational HIV testing.
  • had been a nurse in HIV/AIDS-focus ward or HIV/AIDS case manager.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Get a learning material and a experiential HIV Testing
These participants in the experimental group will be provided a learning material about HIV testing, then an experiential HIV Testing, which includes HIV testing and counselling, education and discussion, and a post-test interviews will be provided.
Other: Experiential HIV Testing
The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
No Intervention: Get a learning material only
These participants in the control group will be provided a learning material about HIV testing only. After the post-test, the experiential HIV Testing will be provided to them.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
HIV Testing Related Knowledge and Practice
Time Frame: pre-test(Baseline) and post-test (week 4)
A self-development scale, known as the "HIV Testing-Related Knowledge and Practice Scale," is employed to assess individuals' knowledge and practices pertaining to HIV testing. The scale consists of twenty-eight questions, encompassing both True-False and multiple-choice formats. Participants earn one point for each correct answer, contributing to a total score that ranges from the minimum scores of 0 to the maximum scores of 28. Higher scores signify a more positive outcome, indicating enhanced HIV testing-related knowledge and practice among the participants.
pre-test(Baseline) and post-test (week 4)
HIV Related Stigma
Time Frame: pre-test (Baseline) and post-test (Week 4)
The Healthcare Provider HIV/AIDS Stigma Scale (HPASS) will be used to assess this outcome. The instrument contains 30 items, each scored on a six-point Likert scale, yielding a minimum total score of 30 and a maximum of 180. Higher scores reflect greater levels of stigma toward people living with HIV, indicating a worse outcome. Validation of the HPASS through factor analysis identified three underlying dimensions. The stereotyping dimension (11 items; score range: 11-66) reflects negative cognitions and beliefs about people living with HIV. The prejudice dimension (13 items; score range: 13-78) captures emotionally driven attitudes. The discrimination dimension (6 items; score range: 6-36) represents behavioral responses stemming from negative attitudes. For all dimensions, higher scores indicate worse outcomes. These 3 dimensions(as sub-scale scores) for stereotyping, prejudice, and discrimination will also be calculated and analyzed.
pre-test (Baseline) and post-test (Week 4)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The demographic factors which affect the effectiveness of experiential HIV testing
Time Frame: one month later
Two-way ANOVA(mixed design) will be used to analyze this outcome.
one month later

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Qualitative analysis of post-test interview in experimental group.
Time Frame: one month later
In order to qualitatively analyses and understands the participants' opinions of the experiential learning, four open-ended questions are applied to the interview in the post-test period. The four questions are: "After experiencing HIV testing, what changes in your mind while waiting for the test results?"; "After experiencing HIV testing, does it make you curious about HIV or want to know more about HIV-related knowledge?"; "After experiencing HIV testing, what changes have you felt towards HIV-related stigma?"; "How and what is this experiential learning method different from traditional lecture class?"
one month later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Taiwan University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: CHENG-RU HE, Bachelor, National Taiwan University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 9, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 1, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 23, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 31, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 8, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 14, 2022

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 1, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 11, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 202209065RINA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings